个人化癌症疫苗市场规模、份额、趋势分析报告：按类型、技术、分销管道、地区、细分市场预测，2025-2030 年

个性化癌症疫苗市场的成长和趋势

根据Grand View Research, Inc.的最新报告，全球个人化癌症疫苗市场规模预计到2030年将达到14.5亿美元，2025年至2030年期间的复合年增长率为44.86%。

免疫疗法、基因组学和 mRNA 技术的融合正在推动市场成长。与传统疫苗不同，这些个人化疗法针对由特定基因突变产生的新抗原，并根据每位患者独特的肿瘤特征进行客製化。这种精确性正在为肿瘤学治疗开闢新的视野，特别是对于难治性癌症。市场成长受到生物技术投资增加、全球癌症发生率上升以及次世代定序仪的进步的推动。从临床试验到监管指定的快速进展，例如 Moderna 获得的欧洲药品管理局 PRIME 指定和默克公司 2023 年 4 月获得的 mRNA-4157/V940 指定，都体现了这一势头。这些疫苗不再是推测性的治疗方法，而是正在成为未来肿瘤学格局中不可或缺的一部分。

市场成长最重要的驱动力之一是基于 mRNA 的疫苗平台的创新。 COVID-19 mRNA 疫苗的成功加速了公共和私营部门对这种治疗方法的信心，从而导致资金筹措增加和监管反应迅速。 Moderna 与默克公司合作开发的临床实验疫苗 mRNA-4157/V940 就是这项进步的一个例子。该疫苗于 2023 年 4 月获得 EMA 的 PRIME 称号，在 2b 期临床试验 (KEYNOTE-942) 中显示出良好的结果，尤其是与默克公司的免疫疗法药物 KEYTRUDA 联合使用时。同样，mRNA 技术的先驱 BioNTech 在 2024 年 4 月的 AACR 年会上展示了其肿瘤学管线，重点关注基于 mRNA 的癌症疫苗和抗体-药物偶联物。这些创新正在为癌症治疗的新时代铺平道路，使研究人员能够根据肿瘤序列快速生成候选疫苗，近乎即时地个人化治疗，并微调免疫反应以提高疗效。

提高全球对 HPV 感染、相关健康风险和疫苗接种益处的认识是推动市场成长的关键因素。公共卫生宣传活动、社群媒体推广和学校教育计画在改变观念和鼓励疫苗接种方面发挥关键作用。拥有强大医疗保健传播策略的国家，如澳洲和英国， 人类乳突病毒(HPV)疫苗接种率明显较高，这反映了持续的基于证据的提高认识工作的有效性。性别中立的疫苗通讯也提高了男性族群的接受度，特别是考虑到男性口咽癌和肛门癌的发生率不断上升。随着性健康耻辱感的消退和越来越多的人意识到疫苗接种的长期预防癌症益处，越来越多的人开始接种疫苗。这种提高意识的努力不仅增加了需求，而且还带来了更早的疫苗接种、更高的遵从率和更稳定的市场成长。

监管奖励在加速个人化癌症疫苗产业发展方面发挥关键作用。 EMA 的 PRIME 计划和 FDA 的突破性疗法认定等项目旨在鼓励开发有前景的严重治疗方法。 Moderna 和 Merck 的 mRNA-4157/V940 疫苗获得 PRIME 认定，证明了监管机构致力于促进肿瘤学创新。该认定基于积极的中期数据，显示高风险 III/IV 期黑色素瘤患者在同时接种该疫苗和 KEYTRUDA 治疗后，术后预后得到改善。同样，BioNTech 参加 AACR2024 等重要科学论坛并发布重要的临床更新，凸显了监管和科学检验的持续加强。此类市场发展将增强投资者信心，加快新型疗法的上市时间，并为治疗选择有限的癌症患者（尤其是在辅助治疗环境中）带来希望。

个人化癌症疫苗市场报告重点

• 按类型划分，受标靶免疫疗法和个人化免疫疗法需求不断增长的推动，树突状细胞预计在 2024 年占据最大的市场占有率，达到 100%。
• 2024年，细胞技术细分市场以100%的收益占有率领先市场，这得益于其能够利用人体免疫系统进行标靶化和适应性的抗肿瘤反应。此细分市场包括利用患者来源细胞（尤其是树突状细胞、肿瘤浸润淋巴细胞 (TIL) 或工程化T细胞）的治疗方法，以呈现肿瘤特异性抗原并刺激针对癌细胞的个人化免疫攻击。
• 医院部门预计将在 2024 年占据市场主导地位，收益占有率为 58.87%，并在预测期内以最快的复合年增长率增长，这主要受以下几个关键因素的推动：医院是癌症诊断、治疗和后续护理的主要中心。
• 在免疫疗法的进步和强大的医疗保健基础设施的推动下，北美在全球市场占据主导地位，2024 年的份额为 34.07%。这一增长是由癌症发病率的上升推动的，仅在美国，2022 年就估计会有 190 万例新的癌症病例。
• 全球个人化疫苗产业由 Dendreon Pharmaceuticals, LLC、Gritstone Bio、CureVac、NeoCura & Innovent、Stemirna Therapeutics、Dendreon Pharmaceuticals, LLC、Elicio Therapeutics、Evaxion BIoTech、Imugene 和 Nouscom 等主要企业伙伴关係

目录

第一章调查方法与范围

第二章执行摘要

3. 个人化癌症疫苗市场变数、趋势与范围

• 市场区隔和范围
• 市场体系展望
  • 母市场展望
  • 相关/支持市场展望
• 市场趋势与展望
• 市场动态
  • 基因组学和免疫治疗技术的进展
  • 癌症发生率上升，标靶治疗需求增加
  • 加强癌症免疫治疗领域的合作与投资
• 市场限制因素分析
  • 开发和製造成本高
  • 监理和物流挑战
  • 波特五力分析
  • PESTEL分析

第四章：个人化癌症疫苗市场：按类型估计和趋势分析

• 个人化癌症疫苗市场：类型变异分析
• 按类型
• 树突状细胞
• 基于RNA（mRNA）
• 基于新抗原
• 肿瘤相关抗原（TAA）疫苗
• 个人化癌症疫苗市场：技术变革分析
• 依技术
• 基于细胞
• mRNA PCV
• 其他的

第五章：个人化癌症疫苗市场：按分销管道的估计和趋势分析

• 个人化癌症疫苗市场：分布波动分析
• 按分销管道
• 医院
• 诊所
• 研究和学术机构

第六章：个人化癌症疫苗市场：区域、估计与趋势分析

• 2024 年及 2030 年个人化癌症疫苗市场占有率（按地区）
• 2024 年及 2030 年区域市场占有率分析
• 区域市场仪表板
• 全球区域市场概况
• 2018-2030年市场规模、预测趋势分析
• 北美洲
  • 2018-2030年北美个人化癌症疫苗市场
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 2018-2030年欧洲个人化癌症疫苗市场
  • 英国
  • 德国
  • 法国
  • 义大利
  • 西班牙
  • 丹麦
  • 瑞典
  • 挪威
• 亚太地区
  • 2018-2030年亚太地区个人化癌症疫苗市场
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 泰国
  • 韩国
• 拉丁美洲
  • 2018-2030年拉丁美洲个人化癌症疫苗市场
  • 巴西
  • 阿根廷
• 中东和非洲
  • 2018-2030年中东及非洲个人化癌症疫苗市场
  • 南非
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 科威特

第七章 竞争态势

• 主要市场参与企业的近期趋势和影响分析
• 公司分类
• 战略地图
• 2024年公司市场占有率分析
• 公司简介
  • Dendreon Pharmaceuticals, LLC
  • Gritstone Bio
  • CureVac
  • NeoCura & Innovent
  • Stemirna Therapeutics
  • Elicio Therapeutics
  • Evaxion BIoTech
  • Imugene
  • Nouscom

Personalized Cancer Vaccine Market Growth & Trends:

The global personalized cancer vaccine market size is expected to reach USD 1.45 billion by 2030, registering a CAGR of 44.86% from 2025 to 2030, according to a new report by Grand View Research, Inc. The convergence of immunotherapy, genomics, and mRNA technologies drives the market growth. Unlike traditional vaccines, these personalized therapies are tailored to each patient's unique tumor profile, targeting neoantigens that arise from specific genetic mutations. This precision has opened new therapeutic horizons in oncology, especially for hard-to-treat cancers. The market growth is propelled by increasing investments in biotechnology, growing incidence of cancer worldwide, and advancements in next-generation sequencing. The rapid progression from clinical trials to regulatory designations, such as the European Medicines Agency's PRIME designation for Moderna and Merck's mRNA-4157/V940 in April 2023, is emblematic of this momentum. These vaccines are no longer speculative treatments; they are becoming integral to the future oncology landscape.

One of the most pivotal drivers of market growth is innovation in mRNA-based vaccine platforms. The success of COVID-19 mRNA vaccines accelerated public and private sector confidence in the modality, leading to increased funding and faster regulatory pathways. Moderna's investigational vaccine, mRNA-4157/V940, developed in partnership with Merck, exemplifies this progress. Granted PRIME designation by the EMA in April 2023, the vaccine showed promising results in Phase 2b trials (KEYNOTE-942), especially when paired with Merck's immunotherapy drug KEYTRUDA. Similarly, BioNTech, a pioneer in mRNA technology, showcased its oncology pipeline at the AACR Annual Meeting in April 2024, highlighting its mRNA-based cancer vaccines and antibody-drug conjugates. These innovations are allowing researchers to rapidly generate vaccine candidates based on tumor sequencing, personalize therapies in near real-time, and fine-tune immune responses to enhance efficacy, paving the way for a new era in cancer treatment.

Increased global awareness regarding HPV transmission, associated health risks, and the benefits of vaccination is a major factor driving market growth. Public health campaigns, social media outreach, and school-based education initiatives have played a pivotal role in changing perceptions and encouraging vaccine acceptance. In countries with robust healthcare communication strategies, such as Australia and the UK, HPV vaccine uptake is notably high, reflecting the impact of consistent, evidence-based awareness efforts. Gender-neutral vaccination messaging has also improved acceptance among male populations, particularly in response to the growing incidence of oropharyngeal and anal cancers in men. As stigma around sexual health diminishes and more people recognize the long-term cancer prevention benefits of vaccination, broader demographic groups are being reached. These awareness initiatives are not only increasing demand but are also leading to earlier vaccination, higher compliance rates, and more consistent market growth.

Regulatory incentives are playing a crucial role in accelerating the personalized cancer vaccine industry. Programs like the EMA's PRIME scheme or the FDA's Breakthrough Therapy designation are designed to expedite the development of promising therapies for serious conditions. Moderna and Merck's mRNA-4157/V940 vaccine receiving PRIME status is a testament to the regulators' commitment to fostering innovation in oncology. This designation was based on positive interim data suggesting that patients with high-risk stage III/IV melanoma had improved outcomes post-surgery when treated with the vaccine alongside KEYTRUDA. Similarly, BioNTech's participation in major scientific forums like AACR 2024, where it revealed significant clinical updates, underscores growing regulatory and scientific validation. These developments help boost investor confidence, shorten time-to-market for novel therapies, and offer hope for cancer patients who have limited treatment options, especially in the adjuvant setting.

Personalized Cancer Vaccine Market Report Highlights:

• Based on type, the dendritic cell segment accounted for the largest market share of 100% in 2024, driven by increasing demand for targeted and individualized immunotherapies.
• The cell-based technology segment led the market with a 100% revenue share in 2024, underpinned by its ability to harness the body's own immune system for targeted and adaptive anti-tumor responses. This segment includes therapies that utilize patient-derived cells, particularly dendritic cells, tumor-infiltrating lymphocytes (TILs), or engineered T-cells, to present tumor-specific antigens and stimulate a personalized immune attack against cancer cells.
• The hospitals segment dominated the market with a revenue share of 58.87% in 2024 and is expected to grow at the fastest CAGR over the forecast period, driven by several key factors. Hospitals serve as primary centers for cancer diagnosis, treatment, and follow-up care
• North America dominated the global market, with a share of 34.07% in 2024, driven by advancements in immunotherapy and a strong healthcare infrastructure. This growth is fueled by the increasing prevalence of cancer, with the U.S. alone reporting an estimated 1.9 million new cancer cases in 2022.
• The global personalized vaccine industry is led by several major companies, including Dendreon Pharmaceuticals, LLC, Gritstone Bio, CureVac, NeoCura & Innovent, Stemirna Therapeutics, Dendreon Pharmaceuticals, LLC, Elicio Therapeutics, Evaxion Biotech, Imugene, and Nouscom, all of which are strengthening their worldwide presence through strategies like launching new products, forging strategic partnerships, and expanding into new geographic regions.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Technology
  • 1.2.3. Distribution Channel
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Technology outlook
  • 2.2.3. Distribution channel outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Personalized Cancer Vaccine Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Trends and Outlook
• 3.4. Market Dynamics
  • 3.4.1. Advances in genomic and immunotherapy technologies
  • 3.4.2. Rising cancer prevalence and demand for targeted treatments
  • 3.4.3. Collaborations and increased investment in cancer immunotherapy
• 3.5. Market Restraint Analysis
  • 3.5.1. High development and manufacturing costs
  • 3.5.2. Regulatory and logistical challenges
  • 3.5.3. Porter's Five Forces Analysis
  • 3.5.4. PESTEL Analysis

Chapter 4. Personalized Cancer Vaccine Market: Type Estimates & Trend Analysis

• 4.1. Personalized Cancer Vaccine Market: Type Movement Analysis
• 4.2. Personalized Cancer Vaccine Market Estimates and Forecast, by Type
• 4.3. Dendritic Cell
  • 4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.4. RNA-Based (mRNA)
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Neoantigen-Based
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Tumor-Associated Antigen (TAA) Vaccines
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Personalized Cancer Vaccine Market: Technology Movement Analysis
• 4.8. Personalized Cancer Vaccine Market Estimates and Forecast, by Technology
• 4.9. Cell-based
  • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.10. mRNA PCV
  • 4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.11. Others
  • 4.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Personalized Cancer Vaccine Market: Distribution Channel Estimates & Trend Analysis

• 5.1. Personalized Cancer Vaccine Market: Distribution Movement Analysis
• 5.2. Personalized Cancer Vaccine Market Estimates and Forecast, by Distribution Channel
• 5.3. Hospitals
  • 5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.4. Clinics
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Research & Academic Institutes
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Personalized Cancer Vaccine Market: Regional Estimates & Trend Analysis

• 6.1. Personalized Cancer Vaccine Market Share By Region, 2024 & 2030
• 6.2. Regional Market Share Analysis, 2024 & 2030
• 6.3. Regional Market Dashboard
• 6.4. Global Regional Market Snapshot
• 6.5. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.6. North America
  • 6.6.1. North America Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.6.2. U.S.
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Competitive Scenario
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. U.S. Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.6.3. Canada
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Competitive Scenario
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Canada Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.6.4. Mexico
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Competitive Scenario
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Mexico Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• 6.7. Europe
  • 6.7.1. Europe Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.7.2. UK
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Competitive Scenario
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. UK Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.7.3. Germany
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Competitive Scenario
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Germany Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.7.4. France
    • 6.7.4.1. Key Country Dynamics
    • 6.7.4.2. Competitive Scenario
    • 6.7.4.3. Regulatory Framework
    • 6.7.4.4. France Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.7.5. Italy
    • 6.7.5.1. Key Country Dynamics
    • 6.7.5.2. Competitive Scenario
    • 6.7.5.3. Regulatory Framework
    • 6.7.5.4. Italy Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.7.6. Spain
    • 6.7.6.1. Key Country Dynamics
    • 6.7.6.2. Competitive Scenario
    • 6.7.6.3. Regulatory Framework
    • 6.7.6.4. Spain Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.7.7. Denmark
    • 6.7.7.1. Key Country Dynamics
    • 6.7.7.2. Competitive Scenario
    • 6.7.7.3. Regulatory Framework
    • 6.7.7.4. Denmark Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.7.8. Sweden
    • 6.7.8.1. Key Country Dynamics
    • 6.7.8.2. Competitive Scenario
    • 6.7.8.3. Regulatory Framework
    • 6.7.8.4. Sweden Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.7.9. Norway
    • 6.7.9.1. Key Country Dynamics
    • 6.7.9.2. Competitive Scenario
    • 6.7.9.3. Regulatory Framework
    • 6.7.9.4. Norway Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• 6.8. Asia Pacific
  • 6.8.1. Asia Pacific Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.8.2. Japan
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Competitive Scenario
    • 6.8.2.3. Regulatory Framework
    • 6.8.2.4. Japan Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.8.3. China
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Competitive Scenario
    • 6.8.3.3. Regulatory Framework
    • 6.8.3.4. China Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.8.4. India
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Competitive Scenario
    • 6.8.4.3. Regulatory Framework
    • 6.8.4.4. India Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.8.5. Australia
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Competitive Scenario
    • 6.8.5.3. Regulatory Framework
    • 6.8.5.4. Australia Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.8.6. Thailand
    • 6.8.6.1. Key Country Dynamics
    • 6.8.6.2. Competitive Scenario
    • 6.8.6.3. Regulatory Framework
    • 6.8.6.4. Thailand Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.8.7. South Korea
    • 6.8.7.1. Key Country Dynamics
    • 6.8.7.2. Competitive Scenario
    • 6.8.7.3. Regulatory Framework
    • 6.8.7.4. South Korea Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• 6.9. Latin America
  • 6.9.1. Latin America Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.9.2. Brazil
    • 6.9.2.1. Key Country Dynamics
    • 6.9.2.2. Competitive Scenario
    • 6.9.2.3. Regulatory Framework
    • 6.9.2.4. Brazil Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.9.3. Argentina
    • 6.9.3.1. Key Country Dynamics
    • 6.9.3.2. Competitive Scenario
    • 6.9.3.3. Regulatory Framework
    • 6.9.3.4. Argentina Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• 6.10. MEA
  • 6.10.1. MEA Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.10.2. South Africa
    • 6.10.2.1. Key Country Dynamics
    • 6.10.2.2. Competitive Scenario
    • 6.10.2.3. Regulatory Framework
    • 6.10.2.4. South Africa Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.10.3. Saudi Arabia
    • 6.10.3.1. Key Country Dynamics
    • 6.10.3.2. Competitive Scenario
    • 6.10.3.3. Regulatory Framework
    • 6.10.3.4. Saudi Arabia Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.10.4. UAE
    • 6.10.4.1. Key Country Dynamics
    • 6.10.4.2. Competitive Scenario
    • 6.10.4.3. Regulatory Framework
    • 6.10.4.4. UAE Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.10.5. Kuwait
    • 6.10.5.1. Key Country Dynamics
    • 6.10.5.2. Competitive Scenario
    • 6.10.5.3. Regulatory Framework
    • 6.10.5.4. Kuwait Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company Categorization
• 7.3. Strategy Mapping
• 7.4. Company Market Share Analysis, 2024
• 7.5. Company Profiles
  • 7.5.1. Dendreon Pharmaceuticals, LLC
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Gritstone Bio
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. CureVac
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. NeoCura & Innovent
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Stemirna Therapeutics
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Elicio Therapeutics
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Evaxion Biotech
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. Imugene
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Nouscom
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives

List of Tables

• Table 1 List of abbreviations
• Table 2 Global Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 3 Global Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 4 Global Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 5 Global Personalized Cancer Vaccine Market, by Region, 2018 - 2030 (USD Million)
• Table 6 North America Personalized Cancer Vaccine Market, by Country, 2018 - 2030 (USD Million)
• Table 7 North America Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 8 North America Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 9 North America Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 10 U.S. Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 11 U.S. Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 12 U.S. Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 13 Canada Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 14 Canada Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 15 Canada Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 16 Mexico Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 17 Mexico Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 18 Mexico Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 19 Europe Personalized Cancer Vaccine Market, by Country, 2018 - 2030 (USD Million)
• Table 20 Europe Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 21 Europe America Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 22 Europe America Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 23 UK Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 24 UK Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 25 UK Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 26 Germany Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 27 Germany Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 28 Germany Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 29 France Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 30 France Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 31 France Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 32 Italy Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 33 Italy Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 34 Italy Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 35 Spain Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 36 Spain Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 37 Spain Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 38 Denmark Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 39 Denmark Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 40 Denmark Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 41 Sweden Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 42 Sweden Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 43 Sweden Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 44 Norway Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 45 Norway Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 46 Norway Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 47 Asia Pacific Personalized Cancer Vaccine Market, by Country, 2018 - 2030 (USD Million)
• Table 48 Asia Pacific Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 49 Asia Pacific Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 50 Asia Pacific Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 51 Japan Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 52 Japan Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 53 Japan Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 54 China Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 55 China Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 56 China Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 57 India Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 58 India Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 59 India Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 60 Australia Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 61 Australia Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 62 Australia Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 63 Thailand Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 64 Thailand Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 65 Thailand Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 66 South Korea Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 67 South Korea Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 68 South Korea Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 69 Latin America Personalized Cancer Vaccine Market, by Country, 2018 - 2030 (USD Million)
• Table 70 Latin America Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 71 Latin America Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 72 Latin America Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 73 Brazil Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 74 Brazil Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 75 Brazil Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 76 Argentina Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 77 Argentina Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 78 Argentina Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 79 Middle East & Africa Personalized Cancer Vaccine Market, by Country, 2018 - 2030 (USD Million)
• Table 80 Middle East & Africa Personalized Cancer Vaccine Market, by type, 2018 - 2030 (USD Million)
• Table 81 Middle East & Africa Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 82 Middle East & Africa Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 83 South Africa Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 84 South Africa Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 85 South Africa Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 86 Saudi Arabia Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 87 Saudi Arabia Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 88 audi Arabia Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 89 UAE Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 90 UAE Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 91 UAE Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 92 Kuwait Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 93 Kuwait Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 94 Kuwait Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information procurement
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value chain-based sizing & forecasting
• Fig. 6 Market formulation & validation
• Fig. 7 Personalized Cancer Vaccine Market segmentation
• Fig. 8 Market snapshot, 2024
• Fig. 9 Market trends & outlook
• Fig. 10 Market driver relevance analysis (current & future impact)
• Fig. 11 Market restraint relevance analysis (current & future impact)
• Fig. 12 SWOT analysis, by factor (political & legal, economic, and technological)
• Fig. 13 Porter's five forces analysis
• Fig. 14 Personalized cancer vaccine market: Type movement analysis
• Fig. 15 Personalized cancer vaccine market: Type outlook and key takeaways
• Fig. 16 Dendritic Cell market estimates and forecast, 2018 - 2030
• Fig. 17 RNA-Based (mRNA) market estimates and forecast, 2018 - 2030
• Fig. 18 Neoantigen-based market estimates and forecast, 2018 - 2030
• Fig. 19 Tumor-Associated Antigen (TAA) vaccines market estimates and forecast, 2018 - 2030
• Fig. 20 Personalized cancer vaccine market: Technology movement analysis
• Fig. 21 Personalized cancer vaccine market: Technology outlook and key takeaways
• Fig. 22 Cell-based market estimates and forecast, 2018 - 2030
• Fig. 23 mRNA PCV market estimates and forecast, 2018 - 2030
• Fig. 24 Others market estimates and forecast, 2018 - 2030
• Fig. 25 Personalized cancer vaccine market: Distribution channel movement analysis
• Fig. 26 Personalized cancer vaccine market: Distribution channel outlook and key takeaways
• Fig. 27 Hospitals market estimates and forecast, 2018 - 2030
• Fig. 28 Clinics market estimates and forecast, 2018 - 2030
• Fig. 29 Research & academic institutes market estimates and forecast, 2018 - 2030
• Fig. 30 Government suppliers market estimates and forecast, 2018 - 2030
• Fig. 31 Regional outlook, 2024 & 2030
• Fig. 32 Global Personalized Cancer Vaccine Market: Region movement analysis
• Fig. 33 North America Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 34 U.S. Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 35 Canada Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 36 Mexico Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 37 Europe Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 38 Germany Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 39 UK Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 40 France Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 41 Italy Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 42 Spain Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 43 Denmark Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 44 Sweden Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 45 Norway Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 46 Asia Pacific Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 47 Japan Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 48 China Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 49 India Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 50 Australia Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 51 South Korea Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 52 Thailand Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 53 Latin America Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 54 Brazil Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 55 Argentina Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 56 Middle East and Africa Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 57 South Africa Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 58 Saudi Arabia Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 59 UAE Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 60 Kuwait Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)